x
Filter:
Filters applied
- Psoriasis
- TNF-αRemove TNF-α filter
- 2017 - 2022Remove 2017 - 2022 filter
Author
- Bivik Eding, Cecilia1
- Brain, Susan D1
- Bíró, Tamás1
- Ekman, Anna-Karin1
- Enerbäck, Charlotta1
- Frueh, Jennifer1
- Gori, Tommaso1
- Gyulai, Rolland1
- Gyömörei, Csaba1
- Horváth, Szabina1
- Kelemen, Balázs1
- Kemény, Ágnes1
- Kodji, Xenia1
- Koenig, Wolfgang1
- Komlódi, Rita1
- Körber, Andreas1
- Mani, Venkatesh1
- Mehta, Nehal N1
- Melzer, Nima1
- Perkecz, Anikó1
- Pinter, Andreas1
- Pintér, Erika1
- Rassaf, Tienush1
- Reich, Kristian1
- Rundquist, Ingemar1
Keyword
- tumor necrosis factor-α3
- CAD1
- cardiovascular1
- CARIMA1
- CI1
- confidence interval1
- coronary artery disease1
- CV1
- Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated with Secukinumab1
- flow-mediated dilation1
- FMD1
- HEKn1
- IMQ1
- KC1
- KO1
- MRI1
- PASI1
- Psoriasis Area and Severity Index1
- PWV1
- RTX1
- TLR1
- TRPA11
- TRPV11
- WT1
Psoriasis
3 Results
- Original Article Stem Cell BiologyOpen Archive
IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis
Journal of Investigative DermatologyVol. 139Issue 7p1564–1573.e8Published online: January 23, 2019- Anna-Karin Ekman
- Cecilia Bivik Eding
- Ingemar Rundquist
- Charlotta Enerbäck
Cited in Scopus: 28Psoriasis is an inflammatory skin disorder characterized by the hyperproliferation of basal epidermal cells. It is regarded as T-cell mediated, but the role of keratinocytes (KCs) in the disease pathogenesis has reemerged, with genetic studies identifying KC-associated genes. We applied flow cytometry on KCs from lesional and nonlesional epidermis to characterize the phenotype in the germinative compartment in psoriasis, and we observed an overall increase in the stemness markers CD29 (2.4-fold), CD44 (2.9-fold), CD49f (2.8-fold), and p63 (1.4-fold). - Original Article Clinical Research: TherapeuticsOpen Access
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
Journal of Investigative DermatologyVol. 139Issue 5p1054–1062Published online: November 30, 2018- Esther von Stebut
- Kristian Reich
- Diamant Thaçi
- Wolfgang Koenig
- Andreas Pinter
- Andreas Körber
- and others
Cited in Scopus: 114Psoriasis increases the risk of cardiovascular (CV) disease. Secukinumab, a fully human monoclonal antibody against IL-17A, shows significant efficacy in psoriasis, but effects on CV markers are unknown. CARIMA (Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated with Secukinumab) was a 52-week, randomized, double-blind, placebo-controlled, exploratory trial in patients with moderate to severe plaque psoriasis without clinical CV disease. Patients were randomly assigned to receive 300 mg or 150 mg secukinumab until week 52 or to receive placebo until week 12 and then 300 mg or 150 mg secukinumab until week 52. - Original Article InflammationOpen Archive
TRPA1 Acts in a Protective Manner in Imiquimod-Induced Psoriasiform Dermatitis in Mice
Journal of Investigative DermatologyVol. 138Issue 8p1774–1784Published online: March 14, 2018- Ágnes Kemény
- Xenia Kodji
- Szabina Horváth
- Rita Komlódi
- Éva Szőke
- Zoltán Sándor
- and others
Cited in Scopus: 41This study revealed the modulatory role of transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) cation channels in the Aldara-induced (5% imiquimod) murine psoriasis model using selective antagonists and genetically altered animals. We have also developed a refined localized model to enable internal controls and reduce systemic effects. Skin pathology was quantified by measuring skin thickness, scaling, blood flow, and analyzing dermal cellular infiltrate, whereas nocifensive behaviors were also observed.